Show Summary Details
Page of

Toward Multi-Omic–Informed Psychotropic Prescribing 

Toward Multi-Omic–Informed Psychotropic Prescribing
Toward Multi-Omic–Informed Psychotropic Prescribing

Abdullah Al Maruf

, and Chad Bousman

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 May 2022

Matching individuals to tolerable and efficacious pharmacotherapies in mental health has proven challenging. As such, efforts to personalize psychotropic prescribing in mental health has received considerable attention over the past decade. This attention has been fueled by technological advances in genomics, specifically, pharmacogenomics, and, more recently, epigenomics, transcriptomics, proteomics, and metabolomics that have facilitated the identification of clinically useful biological markers to guide medication selection and dosing. The convergence of these omic technologies is arguably the future of personalized psychotropic prescribing. This chapter provides an overview of the current genomic, epigenomic, transcriptomic, proteomic, and metabolomic knowledgebase as it relates to psychotropic drug response in an effort to identify promising linkages between and facilitate convergence across these approaches to guide safe and effective pharmacotherapy relevant to psychiatry.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.